Cytotoxic T cells (CTLs) and
Natural Killer (NK) cells are cytotoxic lymphocytes critical to
immune system and are the key players to eliminate cancer cells.
Upon activation, CTLs and NK cells recognize cancer cells and
secrete pore forming protein Perforin and proteases Granzymes that
trigger apoptosis and pyroptosis, leading to cancer cell death.
However, immune checkpoints and immunosuppressive microenvironment
suppress CTL and NK cell activity and thus inhibit anti-tumor
immunity. To develop immune checkpoint inhibitors and enhance
anti-tumor immune responses by targeting immunosuppressive cells
are emerging strategies in immunotherapy. In recent years, chimeric
antigen receptor (CAR)-T and CAR-NK cell therapies have moved into
the spotlight as a powerful tool for immunotherapy.
arigo is proud to introduce the newly
launched Human CTL/
NK Activation Multiplex ELISA Kit (ARG83005)
which is the best solution to examine the activation of CTLs and NK
cells as well as assess the efficacy of immunotherapy. |
